Ignyta STARTRK-2

Update June 2022: This trial remains active but is no longer recruiting in the UK.

STARTRK-2 is an open-label, global, Phase 2 basket study* of entrectinib (RXDX-101) for the treatment of patients with locally advanced or metastatic solid tumours.  Cholangiocarcinoma patients would be screened for an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene rearrangement.

• Ignyta Inc

ClinicalTrials.gov identifier: NCT02568267

For more information go to: https://clinicaltrials.gov/ct2/show/NCT02568267

*The “basket” design means that patient outcomes will be analysed separately, by “basket”, according to tumour type and gene rearrangement.